comprehensive -WSS

comprehensive

author：focus 2025-10-01 20:15:48 - browse：75

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： CZI to create biohub to build anti

focus

WSS

Medical mystery: When a cough is not just a cough

Gilead might be held responsible for not developing a drug

BioAge raises $170M for combination therapy with Zepbound

The dental labor crisis is a moment of opportunity

The Readout: Gilead, Bernie Sanders, and other pharma news

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Wikipedia

comprehensive

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Is there really a nursing shortage in the U.S.?

The cancer drug shortage isn’t new — and neither are the solutions

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Dobbs anniversary: the lost opportunity of abortion as health care

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Alkermes shareholders re

Is there really a nursing shortage in the U.S.?

Anesthesiologist group: stop taking Ozempic before surgery

Biogen Alzheimer’s drug launch off to slow start

explore

For Medicare Advantage, Democrats want stronger protections around AI

Roivant's CEO is a star, but biotech's black hole persists

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Biogen Alzheimer’s drug launch off to slow start

How digital tools helped lower hypertension in marginalized patients

Merck, Daiichi strike cancer drug pact worth up to $22 billion

focus

hotspot

focus

explore